After years of secrecy, Treeline Biosciences disclosed its first three clinical-stage oncology drug candidates, including a protein degrader targeting BCL6 in lymphoma, a KRAS inhibitor with broad mutation coverage, and an EZH2 inhibitor licensed from Hengrui Pharmaceuticals for T-cell lymphoma. The company also raised an additional $200 million in Series A extension funding, bringing total capital raised to $1.1 billion. Treeline’s strategy focuses on building a diversified pipeline of late-stage assets rather than depend solely on milestone-driven funding.